DVY vs XBI
iShares Select Dividend ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.38% for DVY.
- • DVY pays a higher dividend yield (3.37%).
Side-by-side metrics
| Metric | DVY | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.38% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.37% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $22.90B | $10.73B |
YTD return | 13.81% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.57 | 1.10 |
P/E ratio | 15.73 | — |
Last price | $158.60 | $164.01 |
Inception | — | — |
Issuer | iShares | State Street |
DVY top holdings
| MO | Altria Group Inc | 2.26% |
| TROW | T. Rowe Price Group Inc | 2.22% |
| PRU | Prudential Financial Inc | 2.01% |
| PFE | Pfizer Inc | 1.99% |
| OKE | ONEOK Inc | 1.71% |
| HPQ | HP Inc | 1.68% |
| KMB | Kimberly-Clark Corp | 1.68% |
| EIX | Edison International | 1.63% |
| VZ | Verizon Communications Inc | 1.62% |
| F | Ford Motor Co | 1.58% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About DVY
DVY (iShares Select Dividend ETF) is 100 high-dividend-yielding US stocks. Managed by iShares, the fund carries $22.9B in assets under management, an expense ratio of 0.38%, a dividend yield of 3.37%. Its largest holding is Altria Group Inc (MO), which represents 2.3% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 10.1%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.